ScholarIQanswers from OpenAlex & ORCID
Jeffrey R. Infante
ResearcherPublications, citations & collaboration network
Jeffrey R. Infante is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jeffrey R. Infante have?
ScholarIQindexed works
Jeffrey R. Infante has 564 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jeffrey R. Infante have?
ScholarIQcitation count
Jeffrey R. Infante has 31,589 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jeffrey R. Infante?
ScholarIQh-index
Jeffrey R. Infante has an h-index of 79 in OpenAlex.
What is the i10-index of Jeffrey R. Infante?
ScholarIQi10-index
Jeffrey R. Infante has an i10-index of 250 in OpenAlex.
What is the OpenAlex record for Jeffrey R. Infante?
ScholarIQopenalex
The OpenAlex for Jeffrey R. Infante is on the source record.
What are the most-cited papers on Jeffrey R. Infante?
ScholarIQmost cited works
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha, Adam D. Cohen, A. Keith Stewart, Parameswaran Hari, Myo Htut, Alexander M. Lesokhin, Abhinav Deol, Nikhil C. Munshi, Elizabeth O’Donnell, David Avigan, Indrajeet Singh, Enrique Zudaire, Tzu‐Min Yeh, Alicia J. Allred, Yunsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Jenna D Goldberg, Jordan M. Schecter, William Deraedt, Sen Hong Zhuang, Jeffrey R. Infante, Dong Geng, Xiaoling Wu, Marlene J. Carrasco-Alfonso, Muhammad Akram, Farah Hossain, Syed Rizvi, Frank Fan, Yi Lin, Thomas G. Martin, Sundar Jagannath
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
Jeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon, Carlos Becerra, Douglas J. DeMarini, Donna S. Cox, Yanmei Xu, Shannon R. Morris, Vijay Peddareddigari, Ngocdiep T. Le, Lowell L. Hart, Johanna C. Bendell, Gail Eckhardt, Razelle Kurzrock, Keith T. Flaherty, Howard A. Burris, Wells A. Messersmith
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim, Richard Kefford, Anna C. Pavlick, Jeffrey R. Infante, Antoni Ribas, Jeffrey A. Sosman, Leslie A. Fecher, Michael Millward, Grant A. McArthur, Patrick Hwu, René González, Patrick A. Ott, Georgina V. Long, Olivia Gardner, Danièle Ouellet, Yanmei Xu, Douglas J. DeMarini, Ngocdiep T. Le, Kiran Patel, Karl D. Lewis
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Laura Rosiñol, Ajai Chari, Manisha Bhutani, Lionel Karlin, Lotfi Benboubker, Lixia Pei, Raluca Verona, Suzette Girgis, Tara Stephenson, Yusri Elsayed, Jeffrey R. Infante, Jenna D. Goldberg, Arnob Banerjee, María‐Victoria Mateos, Amrita Krishnan